BiotechTube

Durvalumab + SNDX-6352

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Unresectable Intrahepatic Cholangiocarcinoma

Conditions

Unresectable Intrahepatic Cholangiocarcinoma

Trial Timeline

Aug 24, 2021 → Feb 6, 2024

NCT ID
NCT04301778

About Durvalumab + SNDX-6352

Durvalumab + SNDX-6352 is a phase 2 stage product being developed by AstraZeneca for Unresectable Intrahepatic Cholangiocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04301778. Target conditions include Unresectable Intrahepatic Cholangiocarcinoma.

What happened to similar drugs?

1 of 20 similar drugs in Unresectable Intrahepatic Cholangiocarcinoma were approved

Approved (1) Terminated (1) Active (18)
🔄zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
🔄zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
🔄zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
🔄Nivolumab + EverolimusOno PharmaceuticalPhase 3
🔄SHR-1210 + Apatinib + SorafenibJiangsu Hengrui MedicinePhase 3
🔄SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811Jiangsu Hengrui MedicinePhase 3
🔄Durvalumab + Tremelimumab + Cisplatin + Gemcitabine + Carboplatin + GemcitabineAstraZenecaPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04301778Phase 2Completed

Competing Products

20 competing products in Unresectable Intrahepatic Cholangiocarcinoma

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPerspective TherapeuticsPhase 1/2
33
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
33
PLX3397 + vemurafenibDaiichi SankyoPhase 1
21
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
26
zolbetuximabAstellas PharmaPre-clinical
30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44
zolbetuximabAstellas PharmaPre-clinical
33
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
44
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
47
ASP1948Astellas PharmaPhase 1
29
LenvatinibEisaiPhase 2
35
LenvatinibEisaiPhase 1
29
Nivolumab + EverolimusOno PharmaceuticalPhase 3
40
ONO-7913 + ONO-4538 + Fluorouracil + Oxaliplatin + Levofolinate + Bevacizumab + CetuximabOno PharmaceuticalPhase 1
33
SHR-4602Jiangsu Hengrui MedicinePhase 2
42
SHR-1210 + Apatinib + SorafenibJiangsu Hengrui MedicinePhase 3
40
HRS-6209 in Combination with Fulvestrant + HRS-6209 in Combination with HRS-1358 + HRS-6209 in Combination with Letrozole + HRS-6209 in Combination with HRS-8080 + HRS-6209 in Combination with HRS-1358Jiangsu Hengrui MedicinePhase 1/2
39
Camrelizumab + HAIC + TKIJiangsu Hengrui MedicinePhase 2
31
SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811Jiangsu Hengrui MedicinePhase 3
44
Telisotuzumab Adizutecan + Budigalimab + Fluorouracil + Leucovorin + OxaliplatinAbbViePhase 2
42